Perampanel is launched in India in august 2017 as an add on for Partial onset seizures with or without secondary generalisation in adults. Perampanel is the first and only non-competitive AMPA receptor antagonist specifically engineered to block glutamate activity at postsynaptic AMPA receptors. The AMPA receptor is the predominant mediator of excitatory neurotransmission in the brain, implicated in the generation and spread of epileptic activity. Glutamate is the primary neurotransmitter in the central nervous system and research suggest that excessive glutamate can lead to initiation and spread of seizures.

Perampanel was added as a second add on starting with 2 mg once a day and dose build up to 4mg after three weeks. Patients were followed at regular intervals and analysed at the end of 3 months, 6 months and one year. At the end of 3 months none of them stopped the drug and by 6months their seizure frequency reduced by >50 % from baseline in 20 patients (80%) and at the end of one year 18 patients (72%) were seizure free. Except for mild dizziness in couple of patients no adverse affects noted in one-year follow up.